JMD GMP oligos for in vitro Diagnostics
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Prior, T. W.
Right arrow Articles by Bridgeman, S. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Prior, T. W.
Right arrow Articles by Bridgeman, S. J.
JMD 2005, Vol. 7, No. 3
Copyright © 2005 American Society for Investigative Pathology & Association for Molecular Pathology

Experience and Strategy for the Molecular Testing of Duchenne Muscular Dystrophy

Thomas W. Prior and Scott J. Bridgeman

From the Department of Pathology, The Ohio State University, Columbus, Ohio

Mutations in the dystrophin gene result in both Duchenne and Becker muscular dystrophies (DMD and BMD). Approximately two-thirds of the affected patients have large deletions or duplications. Using the multiplex polymerase chain reaction and Southern blotting techniques, the detection of these larger mutations is relatively straightforward. Detection of the point mutations in the remaining one-third of the patients has been challenging, mainly due to the large gene size and lack of hotspots or prevalent mutations. However, with the addition of some of the newer molecular screening methods, it is becoming more feasible for clinical laboratories to test for point mutations in the larger genes like dystrophin. Here we review the clinical features, describe the mutation distributions, evaluate current molecular strategies, and illustrate how the genetic findings have impacted the current clinical diagnostics of Duchenne and Becker muscular dystrophies.




This article has been cited by other articles:


Home page
 PediatricsHome page
J. K. Bobo, A. Kenneson, K. Kolor, and M. A. Brown
Adherence to American Academy of Pediatrics Recommendations for Cardiac Care Among Female Carriers of Duchenne and Becker Muscular Dystrophy
Pediatrics, March 1, 2009; 123(3): e471 - e475.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
P. J Taylor, S. Maroulis, G. L Mullan, R. L Pedersen, A. Baumli, G. Elakis, S. Piras, C. Walsh, B. Prosper-Gutierrez, F. De La Puente-Alonso, et al.
Measurement of the clinical utility of a combined mutation detection protocol in carriers of Duchenne and Becker muscular dystrophy
J. Med. Genet., June 1, 2007; 44(6): 368 - 372.
[Abstract] [Full Text] [PDF]

Home page
 JBJSHome page
L. A. Karol
Scoliosis in Patients with Duchenne Muscular Dystrophy
J. Bone Joint Surg. Am., February 1, 2007; 89(suppl_1): 155 - 162.
[Full Text] [PDF]

Home page
 Clin. Chem.Home page
C.-C. Hung, C.-P. Chen, S.-P. Lin, S.-C. Chien, C.-N. Lee, W.-F. Cheng, W.-S. Hsieh, M. S. Liu, Y.-N. Su, and W.-L. Lin
Quantitative Assay of Deletion or Duplication Genotype by Capillary Electrophoresis System: Application in Prader-Willi Syndrome and Duchenne Muscular Dystrophy
Clin. Chem., December 1, 2006; 52(12): 2203 - 2210.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
J. S. Muller, S. K. Baumeister, U. Schara, J. Cossins, S. Krause, M. v. d. Hagen, A. Huebner, R. Webster, D. Beeson, H. Lochmuller, et al.
CHRND mutation causes a congenital myasthenic syndrome by impairing co-clustering of the acetylcholine receptor with rapsyn
Brain, October 1, 2006; 129(10): 2784 - 2793.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Society for Investigative Pathology and the Association for Molecular Pathology.